ACADIA Pharmaceuticals Inc. (ACAD) Key Metrics
ACAD valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $3.29B
- Enterprise value
- $3.50B
- P/E (TTM)
- 8.6
- Forward P/E
- 25.2
- PEG ratio
- 50.86
- Price / sales
- 2.9 10-yr median 8.4
- Price / book
- 3.4 10-yr median 6.7
- EV / EBITDA
- 35.5
- Dividend yield
- —
- Beta
- 0.89
ACAD key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsACAD valuation Price multiples at each fiscal year-end price.
ACAD returns How much profit the business earns on the capital it uses.
ACAD per-share figures Results divided by the shares outstanding at year-end.
ACAD financial health Debt, liquidity and how easily interest is covered.
ACAD efficiency & capital use Working capital cycle and where the cash goes.
ACAD valuation history
ACAD returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ACAD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ACAD price vs earnings per share
ACAD key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $4.58B | $3.05B | $5.13B | $2.57B | $3.75B | $8.41B | $6.30B | $2.05B | $3.69B | $3.34B |
| Enterprise value | $3.81B | $2.35B | $4.75B | $2.22B | $3.29B | $7.83B | $5.61B | $1.57B | $3.35B | $2.81B |
| P/E ratio | 11.7 | 13.5 | — | — | — | — | — | — | — | — |
| Price / sales | 4.3 | 3.2 | 7.1 | 5.0 | 7.7 | 19.0 | 18.6 | 9.1 | 29.6 | 192.8 |
| Price / book | 3.7 | 4.2 | 11.9 | 6.4 | 6.9 | 13.4 | 9.0 | 4.3 | 11.0 | 6.4 |
| Price / free cash flow | 43.5 | 19.4 | — | — | — | — | — | — | — | — |
| Price / operating cash flow | 41.7 | 19.4 | 307.1 | — | — | — | — | — | — | — |
| EV / sales | 3.6 | 2.5 | 6.5 | 4.3 | 6.8 | 17.7 | 16.5 | 7.0 | 26.8 | 162.3 |
| EV / EBITDA | 25.3 | 23.4 | — | — | — | — | — | — | — | — |
| EV / free cash flow | 36.2 | 14.9 | — | — | — | — | — | — | — | — |
| Earnings yield | 8.5% | 7.4% | −1.2% | −8.4% | −4.5% | −3.3% | −3.7% | −12.0% | −7.8% | −8.1% |
| Free cash flow yield | 2.3% | 5.1% | −0.5% | −4.4% | −3.4% | −1.7% | −2.4% | −8.3% | −5.9% | −6.6% |
| Dividend yield | — | — | — | — | — | — | — | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $26.71 | $18.35 | $31.31 | $15.92 | $23.34 | $53.46 | $42.78 | $16.17 | $30.11 | $28.84 |
| Per share | ||||||||||
| Revenue per share | $6.25 | $5.76 | $4.43 | $3.20 | $3.02 | $2.81 | $2.30 | $1.77 | $1.02 | $0.15 |
| Earnings per share | $2.28 | $1.36 | −$0.37 | −$1.34 | −$1.05 | −$1.79 | −$1.60 | −$1.94 | −$2.36 | −$2.34 |
| Operating cash flow per share | $0.64 | $0.95 | $0.10 | −$0.71 | −$0.78 | −$0.87 | −$1.03 | −$1.32 | −$1.78 | −$1.82 |
| Free cash flow per share | $0.61 | $0.94 | −$0.14 | −$0.71 | −$0.79 | −$0.91 | −$1.03 | −$1.34 | −$1.78 | −$1.90 |
| Cash per share | $4.78 | $4.54 | $2.68 | $2.58 | $3.24 | $4.02 | $4.74 | $3.74 | $2.78 | $4.57 |
| Book value per share | $7.16 | $4.40 | $2.64 | $2.48 | $3.37 | $3.99 | $4.75 | $3.78 | $2.73 | $4.47 |
| Tangible book value per share | $6.53 | $3.68 | $2.24 | $2.48 | $3.37 | $3.98 | $4.73 | $3.75 | $2.69 | $4.41 |
| Dividends per share | — | — | — | — | — | — | — | — | $0.00 | $0.00 |
| Capex per share | $0.03 | $0.00 | $0.24 | $0.00 | $0.01 | $0.05 | $0.01 | $0.02 | $0.01 | $0.08 |
| Debt per share | $0.30 | $0.31 | $0.35 | $0.38 | $0.40 | $0.31 | $0.07 | — | $0.00 | $0.00 |
| Shares outstanding | 171.4M | 166.4M | 163.8M | 161.7M | 160.5M | 157.3M | 147.2M | 126.6M | 122.6M | 115.9M |
| Change in shares outstanding | +3.0% | +1.6% | +1.3% | +0.7% | +2.0% | +6.9% | +16.3% | +3.2% | +5.8% | +15.1% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 39.9% | 38.9% | −14.7% | −45.9% | −28.7% | −42.5% | −39.9% | −60.2% | −67.8% | −75.6% |
| Return on invested capital (ROIC) | 42.9% | 513.4% | −121.2% | −271.3% | −208.4% | −807.2% | — | — | — | — |
| Return on assets (ROA) | 28.4% | 23.4% | −9.2% | −33.5% | −22.6% | −36.0% | −35.6% | −53.0% | −61.2% | −69.3% |
| Return on tangible assets | 26.9% | 21.2% | −9.0% | −36.7% | −24.0% | −36.0% | −30.1% | −45.7% | −76.4% | −49.0% |
| Free cash flow margin | 9.8% | 16.4% | −3.2% | −22.0% | −26.2% | −32.5% | −44.9% | −75.8% | −175.1% | — |
| Income quality (OCF / net income) | 0.28 | 0.70 | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $52.2M | $52.0M | $57.2M | $62.0M | $64.4M | $49.5M | $9.8M | — | $0 | $0 |
| Cash & short-term investments | $819.7M | $756.0M | $438.9M | $416.8M | $520.7M | $632.0M | $697.4M | $473.5M | $341.3M | $529.0M |
| Net debt | −$767.5M | −$704.0M | −$381.7M | −$354.8M | −$456.3M | −$582.4M | −$687.6M | −$473.5M | −$341.3M | −$529.0M |
| Debt / equity | 0.04 | 0.07 | 0.13 | 0.15 | 0.12 | 0.08 | 0.01 | — | 0.00 | 0.00 |
| Debt / assets | 0.03 | 0.04 | 0.08 | 0.11 | 0.09 | 0.06 | 0.01 | — | 0.00 | 0.00 |
| Net debt / EBITDA | −5.09 | −7.03 | — | — | — | — | — | — | — | — |
| Current ratio | 3.83 | 2.38 | 2.42 | 4.04 | 6.43 | 6.77 | 10.16 | 8.83 | 7.62 | 12.87 |
| Quick ratio | 3.71 | 2.32 | 2.28 | 3.99 | 6.35 | 6.68 | 10.08 | 8.76 | 7.51 | 12.77 |
| Interest coverage | — | — | — | -33.8 | -27.2 | -33.5 | -16.5 | — | — | — |
| Working capital | $785.0M | $543.4M | $361.9M | $382.3M | $521.8M | $611.6M | $685.4M | $466.5M | $324.4M | $505.3M |
| Invested capital | $459.9M | $28.8M | $50.1M | $45.6M | $84.6M | $44.6M | $11.5M | $5.6M | −$6.1M | −$10.6M |
| Tangible asset value | $1.12B | $613.0M | $366.3M | $400.4M | $540.9M | $625.9M | $696.5M | $475.0M | $329.7M | $511.4M |
| Net current asset value | $725.3M | $483.4M | $298.9M | $320.5M | $458.6M | $562.0M | $676.2M | $465.0M | $324.3M | $505.2M |
| Graham number | $19.18 | $11.61 | — | — | — | — | — | — | — | — |
| Graham net-net per share | $3.57 | $2.35 | $1.32 | $1.73 | $2.58 | $3.30 | $4.38 | $3.44 | $2.52 | $4.26 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 0.4% | 0.1% | 5.5% | 0.0% | 0.2% | 1.7% | 0.3% | 1.0% | 0.7% | 54.8% |
| Capex / operating cash flow | 4.3% | 0.3% | 239.8% | — | — | — | — | — | — | — |
| Capex / depreciation | 0.40 | 0.03 | 7.21 | 0.00 | 0.34 | 2.59 | 0.41 | 0.71 | 0.30 | 5.20 |
| Stock-based compensation / revenue | 4.9% | 7.0% | 9.1% | 13.2% | 13.1% | 19.1% | 24.3% | 36.4% | 60.5% | 318.9% |
| R&D / revenue | 30.7% | 31.7% | 48.4% | 69.9% | 49.5% | 72.2% | 70.9% | 83.6% | 119.4% | 572.9% |
| SG&A / revenue | 51.2% | 51.0% | 55.4% | 72.4% | 81.8% | 88.0% | 96.0% | 118.7% | 204.2% | 1,085.1% |
| Efficiency | ||||||||||
| Days sales outstanding | 43.1 | 39.5 | 41.6 | 45.3 | 43.6 | 36.4 | 35.3 | 37.7 | 37.4 | 92.4 |
| Days of inventory on hand | 116.1 | 128.8 | 169.4 | 260.6 | 167.5 | 142.3 | 96.9 | 92.8 | 131.7 | 172.9 |
| Days payables outstanding | 55.6 | 75.2 | 120.9 | 352.3 | 146.5 | 139.6 | 96.7 | 119.0 | 177.4 | 231.3 |
| Cash conversion cycle (days) | 103.6 | 93.0 | 90.1 | -46.3 | 64.5 | 39.2 | 35.5 | 11.5 | -8.4 | 34.1 |
| Receivables turnover | 8.47 | 9.25 | 8.78 | 8.06 | 8.37 | 10.02 | 10.33 | 9.68 | 9.77 | 3.95 |
| Payables turnover | 6.57 | 4.85 | 3.02 | 1.04 | 2.49 | 2.62 | 3.77 | 3.07 | 2.06 | 1.58 |
| Inventory turnover | 3.14 | 2.83 | 2.15 | 1.40 | 2.18 | 2.57 | 3.76 | 3.93 | 2.77 | 2.11 |
| Asset turnover | 0.78 | 0.99 | 1.09 | 0.80 | 0.65 | 0.56 | 0.51 | 0.48 | 0.26 | 0.04 |
| Average receivables | $126.5M | $103.5M | $82.7M | $64.2M | $57.8M | $44.1M | $32.8M | $23.1M | $12.8M | $4.4M |
| Average payables | $13.5M | $16.9M | $15.1M | $9.8M | $7.7M | $7.9M | $5.2M | $6.0M | $6.3M | $2.8M |
| Average inventory | $28.3M | $28.9M | $21.2M | $7.3M | $8.8M | $8.0M | $5.2M | $4.7M | $4.7M | $2.1M |
| Intangibles / total assets | 7.0% | 10.1% | 8.7% | 0.0% | 0.0% | 0.1% | 0.3% | 0.8% | 1.4% | 1.3% |
Computed from ACAD's annual financial statements (latest annual report filed February 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ACAD valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), ACADIA Pharmaceuticals traded at 11.7 times earnings. Based on the latest twelve months, the trailing P/E is 8.6 and the forward P/E is 25.2. ACADIA Pharmaceuticals earned a return on equity of 39.9% and a return on invested capital of 42.9% in fiscal 2025. It ended the year with $52.2 million of debt and $819.7 million in cash and short-term investments, a net cash position of $767.5 million. The share count rose 47.9% from 115.9M to 171.4M over 9 years.
See the ACAD income statement, the ACAD chart for price history, or the ACAD stock overview for the latest quote and news.
ACAD key metrics FAQ
What is ACADIA Pharmaceuticals's P/E ratio?
ACADIA Pharmaceuticals's trailing P/E ratio is 8.6 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 25.2. At the end of fiscal 2025 it was 11.7.
What is ACADIA Pharmaceuticals's EV/EBITDA?
ACADIA Pharmaceuticals's enterprise value was 25.3 times EBITDA at the end of fiscal 2025 (enterprise value $3.8 billion, EBITDA $150.7 million); the current EV/EBITDA is 35.5.
What is ACADIA Pharmaceuticals's return on equity?
ACADIA Pharmaceuticals's return on equity (ROE) was 39.9% in fiscal 2025: net income of $391.0 million on average shareholders' equity of $980.1 million.
What is ACADIA Pharmaceuticals's ROIC?
ACADIA Pharmaceuticals's return on invested capital was 42.9% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals had total debt of $52.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.04 and more cash than debt.
What is ACADIA Pharmaceuticals's free cash flow yield?
ACADIA Pharmaceuticals generated $105.1 million of free cash flow in fiscal 2025, a free cash flow yield of 2.3% on its market value at year-end ($4.6 billion).
What is ACADIA Pharmaceuticals's current ratio?
ACADIA Pharmaceuticals's current ratio was 3.83 at the end of fiscal 2025: current assets were 3.83 times current liabilities.